Journal Mobile Options
Table of Contents
Vol. 17, Suppl. 1, 1997
Issue release date: 1997
Int J Microcirc 1997;17:11–17
(DOI:10.1159/000179261)
Paper

Postischemic Leukocyte/Endothelial Cell Interactions and Microvascular Barrier Dysfunction in Skeletal Muscle: Cellular Mechanisms and Effect of Daflon® 500 mg

Korthuis R.J. · Gute D.C.
Department of Physiology, Louisiana State University Medical Center, School of Medicine in Shreveport, La., USA

Abstract

A growing body of evidence indicates that neutrophils play a critical role in disrupting the microvascular barrier in skeletal muscle. Recent studies from our laboratory and by others indicate that administration of antibodies directed against P-selectin, ICAM-1, or the common subunit (CD 18) of CD 11/CD 18 was as effective as neutrophil depletion in attenuating ischemia/ reperfusion (I/R)-induced microvascular barrier disruption and edema formation in skeletal muscle. These studies have important implications with regard to the pathogenesis of leg ulceration in view of our more recent work indicating that the increase in tissue pressure induced by edema formation secondary to microvascular barrier disruption may lead to the development of capillary no-reflow. The resulting maldistribution of blood flow during reperfusion exacerbates muscle injury induced by ischemia. Daflon® 500 mg is a purified, micronized flavonoid fraction that exhibits a number of anti-inflammatory properties and is used clinically to treat venous insufficiency. In view of these actions and the demonstrated role of neutrophil adhesion in the pathogenesis of I/R, we sought to determine whether this agent would prevent leukocyte adhesion and microvascular barrier disruption in postischemic rat cremaster muscles and small bowel. Rats were treated with Dafion 500 mg (80 mg/kg/ day by gavage) or its vehicle for 2 (cremaster studies) or 10 (mesenteric studies) days prior to the experiments. Leukocyte/endothelial cell interactions and venular protein leakage were quantitated using intravital microscopic techniques in rat cremaster muscles and mesenteries subjected to ischemia (60 min for cremaster, 20 min for mesentery) and reperfusion (60 min). The results indicated that Dafion 500 mg was as effective as the anti-adhesive monoclonal antibodies in reducing postischemic leukocyte adhesion and emigration and venular protein leakage in these models.

 goto top of outline Author Contacts

Ronald J. Korthuis, PhD, Department of Physiology, LSU Medical Center, 1501 Kings Highway, Shreveport, LA 71130-3932 (USA), Tel. +1 318 675 6028, Fax +1 318 675 4797, E-Mail rkorth@lsumc.edu


 goto top of outline Article Information

Published online: November 25, 2008
Number of Print Pages : 7


 goto top of outline Publication Details

International Journal of Microcirculation (Clinical and Experimental)

Vol. 17, No. Suppl. 1, Year 1997 (Cover Date: 1997)

Journal Editor: Messmer K. (Munich), Fagrell B. (Stockholm)
ISSN: 0167–6865 (Print), eISSN: NIL (Online)

For additional information: http://www.karger.com/IJC


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.